Antiviral Treatment of Coronavirus Disease-2019 Pneumonia.

ABSTRACT: Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.

SUBMITTER: Radcliffe C 

PROVIDER: S-EPMC9701636 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature